DEXCOM INC

DexCom, Inc. (NASDAQ: DXCM) is a medical device company primarily focused on designing, developing, and commercializing continuous glucose monitoring systems for diabetes and metabolic health management. The company's website is www.dexcom.com.

The company's core product portfolio includes the Dexcom G7 Continuous Glucose Monitoring System, launched in 2023, and the Dexcom G7 15 Day system, launched in late 2025, both of which are integrated CGM systems cleared by the FDA as Class II devices. DexCom also offers the Dexcom ONE+ system in European markets and Stelo, an over-the-counter glucose biosensor launched in August 2024 designed for adults with prediabetes and Type 2 diabetes who do not use insulin. The company's legacy G6 system remains in use with planned transition of customers to newer systems by end of 2026. Complementary offerings include Dexcom Share and Dexcom Follow, remote monitoring systems enabling patients to share glucose data with designated recipients via mobile devices and wearables.

DexCom manufactures its products primarily at facilities in Mesa, Arizona and Penang, Malaysia, with a new manufacturing facility under development in Athenry, Ireland. The company operates a direct sales organization in North America and select international markets, supplemented by distribution arrangements across multiple regions. The company serves patients, caregivers, and clinicians globally, with operations spanning North America, Europe, Asia Pacific, Africa, Latin America, and the Middle East.

The company's technology platform encompasses proprietary sensor technology utilizing biomaterials, membrane systems, electrochemistry, and low-power microelectronics, along with wireless transmitter and receiver technology and compatible mobile device applications. DexCom has established multiple collaboration agreements integrating its CGM products with insulin delivery systems and data platforms from various partners.

DexCom competes in the glucose monitoring market against Abbott Laboratories' Diabetes Care division, Medtronic's diabetes business, Roche Diabetes Care, LifeScan, Ascensia Diabetes Care, and other market entrants. The company emphasizes technological leadership, product performance, ease of use, comprehensive customer support, and rapid innovation as competitive differentiators. Coverage and reimbursement from Medicare, Medicaid, and private third-party payors represent critical elements of the company's commercial success.